Regeneron Pharmaceuticals (NASDAQ:REGN) Director Charles A. Baker sold 15,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $302.67, for a total value of $4,540,050.00. Following the transaction, the director now directly owns 9,000 shares in the company, valued at approximately $2,724,030. The sale was disclosed in a legal filing with the Securities & Exchange Commission. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stock opened today at $311.14 and is currently trading at $315.50. The stock showed a negative weekly performance of -7.29%.
Johnson & Johnson (NYSE:JNJ) has received one of the best news in the recent past after the Arkansas Supreme Court reversed a $1.2 billion penalty judgment imposed on it. The reversal came after the court found out that the state attorney general had sued the company under a law that only applied on drug companies and health care facilities. Johnson & Johnson (NYSE:JNJ) stock opened at $97.51, in current trading session and currently is at $97.73, by gaining 0.36%.The 52 week range of $79.85-$98.17. Company’s market capitalization is $276.50 billion.
VIVUS, Inc. (Nasdaq:VVUS) announced that a review article has been published online in the Journal of Hypertension, the official publication of the International Society of Hypertension and the European Society of Hypertension, summarizing the cardiovascular benefit-risk profile of Qsymia® (phentermine and topiramate extended-release) capsules CIV. The data suggest that Qsymia can be a safe and effective weight loss option for overweight/obese patients with cardiovascular risk factors such as hypertension or type 2 diabetes. VIVUS, Inc. (NASDAQ:VVUS) stock is currently trading at $5.76 .The EPS of the stock is -1.73. Company’s market capitalization is $594.21 million.
On Mar21, 2014 Arena Pharmaceuticals (NASDAQ:ARNA) saw some unusual options trading activity on Friday. Investors purchased 18,110 call options on the company, AmericanBankingNews.com reports. This represents an increase of approximately 330% compared to the average daily volume of 4,215 call options. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened the session at $6.12, and now is at $6.24. The 52 week range of the ARNA stock remained $4.05-$9.25 and the day range was $6.04-$6.27.